Categories: Clinical TrialNews

Alterity Therapeutics to Present at MST Financial Webinar

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data for the Phase 2 open-label study of ATH-434 (202).

Details are listed below:

Webcast details

AUSTRALIA PARTICIPANTS:

  Date:   Thursday, 25 July 2024
  Time:   8:30 a.m. AEST (Sydney/Melbourne)
       

UNITED STATES PARTICIPANTS:

  Date:   Wednesday, 24 July 2024
  Time:   3:30 p.m. Pacific Time
      6:30 p.m. Eastern Time
       

Register for the Zoom webcast:

https://mstfinancial-au.zoom.us/webinar/register/WN_8zfACjD8TqO7SsMcAyxzkg

Registration is required and dial in details will be sent directly upon registration.

Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064

U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386

Staff

Recent Posts

PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer

Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)…

3 minutes ago

TranscribeGlass Places Multiple Follow-on Orders for Vuzix Z100 Smart Glasses

– AI-driven speech to text wearable transcription enhances accessibility for the deaf or hard of…

3 minutes ago

Local Innovation, Local Impact: Avive Solutions and City of Brisbane Set New Standard in Community AED Preparedness

SAN FRANCISCO, June 30, 2025 /PRNewswire/ -- In a powerful demonstration of public safety innovation and…

4 minutes ago

AI leader Vasi Philomin joins Siemens to scale Industrial AI innovation

Strategic hire strengthens Siemens' leadership in industrial AIReporting to Peter Koerte, Member of the Managing…

4 minutes ago

BayCare Information Services Names Two New Vice Presidents

CLEARWATER, Fla., June 30, 2025 /PRNewswire/ -- BayCare has named Patrick Brown, MD, FAAP, as…

4 minutes ago

Affordable Ceretone OTC Hearing Aids Now Available at Target Stores Nationwide

LOS ANGELES, June 30, 2025 /PRNewswire/ -- Ceretone, a pioneering force in affordable hearing technology, today…

4 minutes ago